The Phase III Embla study demonstrated a significant PFS improvement with talazopanib monotherapy versus standard chemotherapy in patients with metastatic HER2-negative BRCA-mutated breast cancer [67]. This evidence concerns the gene ERBB2 and breast carcinoma.